Therapeutics– tag –
-
Oncology Drug Approval News Flash FDA approves nivolumab (Opdivo) with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma (and converts prior accelerated approvals in relapsed/refractory cHL to traditional approval)
On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classica... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A3: Why Solid Tumors Are Hard for CAR-T — The 3 Core Barriers [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) What yo... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B2: Toxicity Management, Site Operations & Long-Term Safety (Including Regulatory Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to m Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + inde... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A2: CAR-T Side Effects Without Panic — What Can Happen & What to Monitor [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Tod New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Ther... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B1: FDA-Approved CAR-T Landscape (Products, Targets, Companies, Label Logic) [Expert]
Eleven CAR-T products have earned FDA approval, each targeting a specific cell, antigen, and disease. A single well-made table is worth a month of white papers—here is how to read it, and where the next approvals will land. Prefer the be... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A1: Where CAR-T Is Used Today — The Big Picture (Blood Cancers First) [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Ind New here? If you haven’t read the introduction, it will make this post much easier to ... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A0: What Is CAR-T Therapy? The Big Picture, in Plain Language [Beginner]
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move This series explains CAR-... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
Oncology Drug Approval News Flash: Encorafenib plus cetuximab and fluorouracil-based chemotherapy receives traditional FDA approval for BRAF V600E–mutated metastatic colorectal cancer
FDA approval summary On February 24, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorourac... -
New Series Untangling Cancer Worries: Organ-by-Organ Basics at a Glance — Episode 3: Worried About Stomach Cancer? Understanding H. pylori, Endoscopy, and Follow-up Calmly
“My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening result says I need follow-up.” “I tested positive for H. pylori.” St “My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening resu... -
New Series: Untangling Cancer Worries: Organ-by-Organ Basics at a Glance — Episode 4: Breast Cancer—What to Know First After Noticing a Lump (The Testing Pathway)
“Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer searches can quickly become overwhelming. “Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer s... -
New Series Episode 2: If Colorectal Cancer Is on Your Mind—A Calm, Gentle Overview of Symptoms, Tests, Staging, and Treatment | Untangling Cancer Worries: Organ-by-Organ Basics at a Glance
“I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool test came back positive.” Once you start searching, the amount of i “I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool tes... -
Series: Untangling Cancer Worries — Your First GuidePart 8: Lung Cancer Basics—A Calm Map of Tests, Staging, and Treatment Flow (With When-to-Seek-Care Signs)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstCommon entr... -
Series: Untangling Cancer Worries — Your First GuidePart 7: How to Read “Breakthrough Treatment” News Without Panic—Focus Only on What Matters in Real Life
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstThe three t... -
Series: Untangling Cancer Worries — Your First GuidePart 6: What Is a Rare Cancer? How to Search When Information Is Limited—and What to Ask Clinicians
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is a “... -
Oncology Drug Approval News Flash: Optune Pax, a low electric field tumor treating fields device, approved with gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p... -
Series: Untangling Cancer Worries — Your First GuidePart 5: Genetic Variants and Cancer Risk — What Tests Can Tell You (and What They Can’t)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Series: Untangling Cancer Worries — Your First Guide Part 4: Benign vs Malignant Tumors — What the Words Mean (and What to Confirm First)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Series: Untangling Cancer Worries — Your First Guide Part 3: What Does “Metastasis” Mean? How It Differs From Stage—and How Treatment Plans Can Change
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is met... -
Oncology Drug Approval News Flash: Pembrolizumab plus paclitaxel with or without bevacizumab approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with...
